newsfilter
← Latest News
GlobeNewswire·

Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results

  • Cocrystal Pharma completed dosing for the last subject in its Phase 1b challenge study of CDI-988 for norovirus prevention & treatment in September 2026 with no serious adverse events reported.
  • Preliminary efficacy results from the Phase 1b study are expected near the end of 2026.
  • The company raised $5 million through a private placement with OPKO Health, selling approximately 5.47 million shares at $0.9134 per share.
  • Carol Brosgart, MD, an antiviral drug development leader, was appointed to the Board of Directors in August 2026.
  • CDI-988 received FDA Fast Track designation in April 2026 & is currently being evaluated for both prevention & treatment of norovirus strains including GII.2.
  • The Phase 1b study enrolled 32 healthy adults at Emory University School of Medicine to evaluate safety, viral shedding, & clinical symptom reduction.
  • The company reported $105,000 revenue for the three months ended September 30, 2026, and $435,000 for the nine-month period, primarily from NIH SBIR grants.
  • Net loss for the three months ended September 30, 2026, was $3.444 million, while the net loss for the nine months ended September 30, 2026, was $8.907 million.
  • Research & development expenses increased significantly in 2026 due to costs associated with the CDI-988 Phase 1b norovirus challenge study.
  • Cocrystal reported unrestricted cash of $4.873 million as of September 30, 2026, following the OPKO Health private placement.
  • The company continues development of CC-42344 for influenza A, with plans for an additional Phase 2a study after initial trial conduct issues prevented efficacy reporting in 2025.
  • An approximately $500,000 SBIR Phase I grant was awarded in October 2025 to support a novel influenza A/B polymerase complex inhibitor program.
Company
Cocrystal Pharma, Inc.
Keywords
Nasdaq:COCP, Cocrystal Pharma, Inc., Cocrystal Pharma, Inc, Nasdaq: COCP, antiviral product pipeline, Reports Third Quarter, 2026 Financial Results, Business Update